Explore evidence

15.6 %Tuberculosis prevalence was 15.6% at HIV Stage I, 36.44% at Stage II, and 51.7% at Stage III.

Congotuberculose · VIH/sidaobserved 2021published 2026BMC infectious diseaseseurope_pmcdocument of 7 observations

60 %During the 2014–16 Ebola virus disease outbreak in West Africa, only 60% of patients were laboratory confirmed.

Congomaladie à virus Ebolaobserved 2014-16published 2019Expert review of molecular diagnosticseurope_pmcdocument of 2 observations

COVID-19 and tuberculosis (TB) were the top two leading causes of death from a single infectious agent in 2022.

CongoCOVID-19 · tuberculoseobserved 2022published 2025Journal of public health in Africaeurope_pmcdocument of 4 observations

11.6 %Treatment interruption occurred in 11.6% of HIV patients.

CongoVIH/sidaobserved 2021published 2026BMC infectious diseaseseurope_pmcdocument of 7 observations

0.52 correlation_coefficientThere was a strong positive correlation between IgA in saliva and plasma (r = 0.52).

CongoCOVID-19published 2023Immunity, inflammation and diseaseeurope_pmcdocument of 4 observations

51 %The proportion of tuberculosis/HIV co-infected patients on antiretroviral therapy in the Republic of Congo increased by 51% from 2016 to 2023.

Congotuberculosis/HIVobserved 2016 to 2023published 2025BMJ global healthPubMeddocument of 8 observations

36.44 %Tuberculosis prevalence was 36.44% at HIV Stage II.

Congotuberculose · VIH/sidaobserved 2021published 2026BMC infectious diseaseseurope_pmcdocument of 7 observations

Inactivated and recombinant COVID-19 vaccines in use in the Republic of Congo poorly activated mucosal IgA-mediated antibody response 2 months postvaccination.

CongoCOVID-19observed 2 months postvaccinationpublished 2023Immunity, inflammation and diseaseeurope_pmcdocument of 4 observations

67.5 %Out of 409 participants, 67.5% had good knowledge towards COVID-19.

CongoCOVID-19published 2025Journal of public health in Africaeurope_pmcdocument of 4 observations

51.7 %Tuberculosis prevalence was 51.7% at HIV Stage III.

Congotuberculose · VIH/sidaobserved 2021published 2026BMC infectious diseaseseurope_pmcdocument of 7 observations

1,000 times_lowerThe overall IgG and IgA levels were respectively over 10^3 and 14 times lower in saliva than in plasma samples.

CongoCOVID-19published 2023Immunity, inflammation and diseaseeurope_pmcdocument of 4 observations

61 %Most of the HIV positive patients were women: 311 out of 510 (61%).

CongoVIH/sidaobserved 2021published 2026BMC infectious diseaseseurope_pmcdocument of 7 observations

-13.9 per_yearThe rate of tuberculosis patients testing HIV positive in the Republic of Congo decreased with an annual percentage change of -13.9 from 2016 to 2023.

Congotuberculoseobserved 2016 to 2023published 2025BMJ global healthPubMeddocument of 8 observations

2.6 %From 2016 to 2023, the tuberculosis incidence rate in the Republic of Congo decreased by 2.6%.

Congotuberculoseobserved 2016 to 2023published 2025BMJ global healthPubMeddocument of 8 observations

54 %Out of 409 participants, 54% had a favourable attitude towards COVID-19.

CongoCOVID-19published 2025Journal of public health in Africaeurope_pmcdocument of 4 observations

4.9 per_yearThe proportion of unsuccessful tuberculosis treatment outcomes in the Republic of Congo showed a non-significant annual percentage change of 4.90% from 2016 to 2023.

Congotuberculoseobserved 2016 to 2023published 2025BMJ global healthPubMeddocument of 8 observations

22 %Tuberculosis treatment coverage in the Republic of Congo rose by 22% from 2016 to 2023.

Congotuberculoseobserved 2016 to 2023published 2025BMJ global healthPubMeddocument of 8 observations

0.7 correlation_coefficientThere was a strong positive correlation between IgG in saliva and plasma (r = 0.70).

CongoCOVID-19published 2023Immunity, inflammation and diseaseeurope_pmcdocument of 4 observations

58.6 %The proportion of cases with elevated BMI was 58.6% in HIV Stage III.

CongoVIH/sidaobserved 2021published 2026BMC infectious diseaseseurope_pmcdocument of 7 observations

4.2 per_yearThe proportion of bacteriologically confirmed tuberculosis cases in the Republic of Congo increased with an annual percentage change of 4.2 from 2016 to 2023.

Congotuberculoseobserved 2016 to 2023published 2025BMJ global healthPubMeddocument of 8 observations

3.76 per_yearTuberculosis-related deaths in the Republic of Congo increased with a non-significant annual percentage change of 3.76% from 2016 to 2023.

Congotuberculoseobserved 2016 to 2023published 2025BMJ global healthPubMeddocument of 8 observations

22.5 %Out of 409 participants, 22.5% had good practices towards COVID-19.

CongoCOVID-19published 2025Journal of public health in Africaeurope_pmcdocument of 4 observations

68 percent_greater_thanThe wild type Pfmdr1 N86 allele was predominant (> 68%) in a study of 1001 Plasmodium falciparum-infected blood samples from asymptomatic malaria pregnant women in Brazzaville, Republic of Congo.

Congopaludismepublished 2020Malaria journaleurope_pmcDOI 10.1186/s12936-020-03246-0

11,308 deathsThe 2014–16 outbreak of Ebola virus disease in West Africa resulted in 11,308 deaths.

Congomaladie à virus Ebolaobserved 2014-16published 2019Expert review of molecular diagnosticseurope_pmcdocument of 2 observations

25 per_yearThe proportion of notified tuberculosis patients tested for HIV in the Republic of Congo increased with an annual percentage change of 25 from 2016 to 2023.

Congotuberculoseobserved 2016 to 2023published 2025BMJ global healthPubMeddocument of 8 observations